2017 was a strong year for life sciences IPOs, with more than 40 biopharma companies going public. Deal values increased from the previous year, as innovation in the industry hit an all-time high and the markets took notice. As life sciences companies continue to develop new products for commercialization, it is important to understand how the market will value preclinical companies and what financing options these companies will be able to successfully pursue. Our panel will share their perspectives on the financing landscape for preclinical life sciences companies and what we might expect going forward.

Session ID: 426183